Results Obtained with N-Ottil-enolic-ether of Dihydrotestosterone in Advanced Breast Cancer

Twenty-five women with advanced breast cancer were treated with n-ottil-enolic-ether of dihydrotestosterone. Objective regression of all lesions or of part of them was observed in 8 patients (32% of the cases), with an average duration of 5.5 months (max. 9 months). The highest incidence of regression was observed in lesions of soft tissues in patients in advanced post-climaterium. Subjective results were good, especially on pain caused by bone metastases, even in the absence of an objective regression of the neoplastic localization. There were mild side effects; a slight hypertricosis was observed in 6 patients. The authors emphasize the analogy between the incidence, type and degree of neoplastic regressions obtained with the present compound and those obtained with testosterone propionate. They conclude that the antitumoral effect of this class of steroids is not necessarily related to the degree of their androgen or gonadotropic activity.